ARS Pharmaceuticals, Inc. to Participate in Piper Sandler 37th Annual Healthcare Conference

ARS Pharmaceuticals will participate in the Piper Sandler Healthcare Conference, featuring a fireside chat and investor meetings.

Quiver AI Summary

ARS Pharmaceuticals, Inc. has announced its participation in the Piper Sandler 37th Annual Healthcare Conference, taking place from December 2-4, 2025, in New York. During the conference, Richard Lowenthal, Co-Founder and CEO, and Eric Karas, Chief Commercial Officer, will engage in a fireside chat on December 3 at 2:30 pm ET, facilitated by analyst David Amsellem. The company will also hold one-on-one meetings with investors. A live webcast of the session will be available on their website, along with a replay for 90 days. ARS Pharma focuses on providing solutions for at-risk patients facing allergic reactions leading to anaphylaxis, notably through its product neffy®, an epinephrine nasal spray approved for emergency treatment in both the U.S. and EU.

Potential Positives

Participation in a major healthcare conference enhances visibility and credibility for ARS Pharmaceuticals among investors and industry peers.
Fireside chat with a reputable Piper Sandler analyst provides an opportunity for direct engagement and presentation of the company's strategic vision and growth plans.
Live webcast and replay of the discussion offer extended reach, allowing stakeholders who could not attend the conference to access important company information.
Emphasis on the company's focus on empowering at-risk patients positions ARS Pharmaceuticals positively in the growing biopharmaceutical market for allergy treatments.

Potential Negatives

Participation in the conference may indicate a need for increased visibility and investor communication, suggesting potential concerns about the company's current standing or market perception.
Company management's participation in one-on-one meetings with investors could imply a desire to rebuild investor confidence or address questions about the company's performance or future prospects.
As a biopharmaceutical company focusing on life-saving treatments, any delays or issues related to their product launch or market penetration, although not mentioned in the release, could pose significant risks not addressed.

FAQ

What is ARS Pharmaceuticals' upcoming event?

ARS Pharmaceuticals will participate in the Piper Sandler 37th Annual Healthcare Conference from December 2-4, 2025, in New York.

Who will represent ARS Pharmaceuticals at the conference?

Richard Lowenthal, CEO, and Eric Karas, Chief Commercial Officer, will represent ARS Pharmaceuticals at the conference.

What is the focus of ARS Pharmaceuticals?

ARS Pharmaceuticals focuses on empowering at-risk patients and their caregivers to prevent allergic reactions leading to anaphylaxis.

How can I watch the fireside chat?

A live webcast of the fireside chat on December 3 will be available on the Company’s website and archived for 90 days.

What product does ARS Pharmaceuticals commercialize?

The company commercializes neffy®, an epinephrine nasal spray for emergency treatment of allergic reactions, including anaphylaxis.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$SPRY Insider Trading Activity

$SPRY insiders have traded $SPRY stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $SPRY stock by insiders over the last 6 months:

JAMES E FLYNN has made 0 purchases and 2 sales selling 740,149 shares for an estimated $13,663,150.
JUSTIN CHAKMA (Chief Business Officer) has made 0 purchases and 2 sales selling 166,380 shares for an estimated $1,476,147.
RICHARD E LOWENTHAL (PRESIDENT AND CEO) sold 50,000 shares for an estimated $724,345
SARINA TANIMOTO (CHIEF MEDICAL OFFICER) has made 0 purchases and 2 sales selling 50,000 shares for an estimated $703,755.
ERIC KARAS (Chief Commercial Officer) has made 0 purchases and 2 sales selling 30,000 shares for an estimated $494,860.
BRIAN DORSEY (Chief Operating Officer) sold 21,828 shares for an estimated $190,049
KATHLEEN D. SCOTT (Chief Financial Officer) sold 12,500 shares for an estimated $187,500

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$SPRY Hedge Fund Activity

We have seen 113 institutional investors add shares of $SPRY stock to their portfolio, and 101 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RUBRIC CAPITAL MANAGEMENT LP added 3,205,122 shares (+247.5%) to their portfolio in Q3 2025, for an estimated $32,211,476
DEERFIELD MANAGEMENT COMPANY, L.P. removed 2,220,696 shares (-22.8%) from their portfolio in Q3 2025, for an estimated $22,317,994
ADAGE CAPITAL PARTNERS GP, L.L.C. removed 1,728,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $17,366,400
CASDIN CAPITAL, LLC added 1,600,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $16,080,000
ABERDEEN GROUP PLC added 1,594,447 shares (+106.1%) to their portfolio in Q3 2025, for an estimated $16,024,192
WELLINGTON MANAGEMENT GROUP LLP removed 1,433,187 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $14,403,529
OCTAGON CAPITAL ADVISORS LP removed 1,350,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $13,567,500

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$SPRY Analyst Ratings

Wall Street analysts have issued reports on $SPRY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Roth Capital issued a "Buy" rating on 09/04/2025

To track analyst ratings and price targets for $SPRY, check out Quiver Quantitative's $SPRY forecast page.

Full Release

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37 ^th Annual Healthcare Conference, December 2-4, 2025, in New York.

Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in a fireside chat on Wednesday, December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. Company management will also participate in one-on-one meetings with investors.

A live webcast of the fireside chat will be available here , and in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.

About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EUR neffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com .

Investor Contact:
Justin Chakma, ARS Pharma
[email protected]

Media Contact:
Christy Curran, Sam Brown Inc.
[email protected]
615.414.8668